Bottom line
BBH vs IBB: the short answer
BBH (VanEck Biotech ETF) and IBB (iShares Biotechnology ETF) share a meaningful slice of their top holdings — about 66% by weight.
But IBB is far broader, holding 254 positions to 25 for BBH, so beyond the top names it adds exposure BBH doesn't have.
BBH is cheaper at 0.35% vs 0.44% — a difference of $9.00 a year per $10,000 invested.
Over five years, BBH returned +2.7% a year vs +2.5% for IBB.
Updated Nov 19, 2026
BBH vs IBB side by side
| BBH | IBB | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | VanEck | iShares |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.35% | 0.44% |
| Annual cost per $10k | $35 | $44 |
| 10-yr cost on $10k (prospectus) | $443 | $555 |
| Max front load | None | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +21.2% | +28.0% |
| 5-yr return (annualized) | +2.7% | +2.5% |
| 10-yr return (annualized) | +4.5% | +4.4% |
| Best quarter | +27.6% | +26.8% |
| Worst quarter | −18.2% | −22.9% |
| Net assets (fund) | $395.6M | $5.9B |
| Number of holdings | 25 | 254 |
| Portfolio turnover | 19% | 27% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BBH | IBB | Difference |
|---|---|---|---|
| 2025 | +21.2% | +28.0% | −6.9% |
| 2024 | −4.4% | −2.4% | −2.0% |
| 2023 | +3.9% | +3.6% | +0.2% |
| 2022 | −15.1% | −13.6% | −1.5% |
| 2021 | +11.8% | +1.0% | +10.8% |
| 2020 | +22.1% | +25.9% | −3.9% |
| 2019 | +25.8% | +24.8% | +1.0% |
| 2018 | −10.2% | −9.1% | −1.1% |
| 2017 | +16.6% | +21.2% | −4.6% |
| 2016 | −15.0% | −21.5% | +6.5% |
Source: Fund prospectus bar charts
Holdings overlap
17 of BBH's top 25 holdings also appear in IBB's top 25.
| Holding | BBH | IBB |
|---|---|---|
| Amgen Inc | 15.25% | 7.50% |
| Gilead Sciences Inc | 12.79% | 7.52% |
| Vertex Pharmaceuticals Inc | 9.10% | 7.66% |
| Regeneron Pharmaceuticals Inc | 6.21% | 5.70% |
| Argenx SE | 4.97% | 3.15% |
| Natera Inc | 4.92% | 2.11% |
| IQVIA Holdings Inc | 4.31% | 3.18% |
| Alnylam Pharmaceuticals Inc | 3.83% | 5.68% |
| Biogen Inc | 3.63% | 2.03% |
| Moderna Inc | 3.36% | 0.88% |
| Illumina Inc | 3.17% | 1.41% |
| United Therapeutics Corp | 2.83% | 1.82% |
| BeOne Medicines Ltd | 2.81% | 2.11% |
| Insmed Inc | 2.67% | 2.95% |
| Incyte Corp | 2.49% | 1.62% |
Source: SEC Form N-PORT
BBH top 10
- Amgen Inc — 15.25%
- Gilead Sciences Inc — 12.79%
- Vertex Pharmaceuticals Inc — 9.10%
- Regeneron Pharmaceuticals Inc — 6.21%
- Revolution Medicines Inc — 5.27%
- Argenx SE — 4.97%
- Natera Inc — 4.92%
- IQVIA Holdings Inc — 4.31%
- Alnylam Pharmaceuticals Inc — 3.83%
- Biogen Inc — 3.63%
IBB top 10
- BlackRock Funds III — 13.18%
- Vertex Pharmaceuticals, Inc. — 7.66%
- Gilead Sciences, Inc. — 7.52%
- Amgen, Inc. — 7.50%
- Regeneron Pharmaceuticals, Inc. — 5.70%
- Alnylam Pharmaceuticals, Inc. — 5.68%
- IQVIA Holdings, Inc. — 3.18%
- Argenx SE — 3.15%
- Insmed, Inc. — 2.95%
- Mettler-Toledo International, Inc. — 2.49%
FAQ
What is the difference between BBH and IBB?
Which is cheaper, BBH or IBB?
Should I own both BBH and IBB?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.